Form 4: KalVista Pharmaceuticals Chief Development Officer Reports PSU Vesting and Tax-Related Stock Sale

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, reported the vesting of 60,000 performance stock units and a subsequent sale of 30,250 shares to cover tax withholding obligations.

Summary

• Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, Inc., acquired 60,000 shares of common stock on July 8, 2025.
• These shares were earned upon the 100% vesting of performance stock units (PSUs) granted on January 11, 2023, due to the achievement of specified performance data metric goals.
• Following this acquisition, Christopher Yea's beneficial ownership increased to 158,189 shares.
• On July 9, 2025, Christopher Yea disposed of 30,250 shares of common stock at a price of $15.6925 per share.
• This sale was a "sell to cover" transaction, specifically executed to satisfy tax withholding obligations related to the PSU vesting and settlement, and was not a discretionary transaction.
• After the sale, Christopher Yea's beneficial ownership stands at 127,939 shares.

Sentiment

Score: 7

Explanation: The vesting of 100% of performance stock units indicates the achievement of company performance metrics, which is a positive sign. The subsequent sale was non-discretionary and solely for tax purposes, thus not reflecting negative sentiment from the insider.

Positives

• 100% of the performance stock units (PSUs) granted to the Chief Development Officer vested, indicating the achievement of performance data metric goals by KalVista Pharmaceuticals.
• The vesting of PSUs demonstrates the company's success in meeting its pre-defined performance metrics.

Future Outlook

NA

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs.
• The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This filing reflects a routine insider transaction common in the biotechnology and pharmaceutical sectors where executive compensation often includes performance-based equity awards. The vesting of PSUs tied to 'Performance Metrics' suggests the company has met specific operational or developmental milestones, which is a positive indicator within the industry.

Comparison to Industry Standards

• The use of Performance Stock Units (PSUs) as part of executive compensation is a standard practice across the biotechnology and pharmaceutical industries, aligning executive incentives with company performance.
• "Sell to cover" transactions for tax obligations upon equity vesting are also a common and expected mechanism for executives to manage tax liabilities without engaging in discretionary sales that might signal a change in sentiment about the company's prospects.

Stakeholder Impact

• Shareholders: The vesting of PSUs indicates the company met performance goals, which could be viewed positively. The "sell to cover" transaction is a routine event and not indicative of a lack of confidence from the Chief Development Officer.
• Employees: The achievement of performance metrics that led to PSU vesting could signal a positive operational environment and successful execution of company strategy.

Key Dates

Keywords

KalVista Pharmaceuticals, KALV, SEC Form 4, Insider Trading, Stock Transaction, Performance Stock Units, PSU Vesting, Chief Development Officer, Christopher Yea, Sell to Cover, Tax Withholding